Composition, form of production and packaging
Drops for ingestion are yellowish-orange in color, transparent, with mild opalescence.
1 ml
ubedecarenone 30 mg
Excipients:? -tocopherol acetate, ascorbyl palmitate, macrogol glyceryl hydroxy stearate (Cremophor RH-40), sodium benzoate, citric acid (food), purified water.
15 ml - bottles of light-protective glass (1) with stoppers-droppers - packs cardboard.
20 ml - bottles of light-protective glass (1) with stoppers-droppers - packs cardboard.
25 ml - bottles of light-protective glass (1) with stoppers-droppers - packs cardboard.
50 ml - bottles of light-protective glass (1) with stoppers-droppers - packs cardboard.
60 ml - bottles of light-protective glass (1) with stoppers-droppers - packs cardboard.
100 ml - bottles of light-protective glass (1) with stoppers-droppers - packs cardboard.
INSTRUCTION FOR THE SPECIALIST.
Description of the drug approved by the manufacturer for the printed edition of 2011.
PHARMACHOLOGIC EFFECT
A drug that normalizes the metabolism of the myocardium, which reduces tissue hypoxia. Ubidekarenone (coenzyme Q 10 , ubiquinone) is a natural substance that is a vitamin-like coenzyme. Ubidecarenone is an endogenous substrate, participates in the transport of electrons in the transport chain of oxidation-reduction processes, during energy metabolism, in the oxidative phosphorylation reaction in the respiratory chain of mitochondria of cells. Participates in the processes of cellular respiration, increasing the synthesis of ATP.
Has a clinically significant antioxidant effect. Protects the lipids of cell membranes from peroxidation.
Reduces the area of ​​damage to the myocardium under conditions of ischemia and reperfusion. Ubidekarenon prevents the prolongation of the QT interval, improves the tolerance of exercise.
Due to endogenous synthesis 100% satisfaction of the body's need for coenzyme Q 10 occurs only up to the age of 20 years. Concentration of coenzyme Q 10decreases in elderly patients, as well as in various diseases in both adults and children.
PHARMACOKINETICS
Data on the pharmacokinetics of the drug are not available.
INDICATIONS
Adults:
For prevention and in the complex therapy of various diseases of the cardiovascular system:
- Chronic heart failure (including dilated cardiomyopathy);
- IHD, incl. myocardial infarction (during the period of rehabilitation therapy);
- arrhythmia;
- arterial hypertension;
- the period of preparation for cardiac surgery (coronary artery bypass grafting, for heart defects).
Children over 1 year old:
For prevention and as part of complex therapy:
- diseases of the cardiovascular system: arrhythmia, chronic heart failure (including dilated cardiomyopathy), the period of preparation for cardiac surgery (congenital and acquired defects);
- Gastrointestinal diseases: chronic gastroduodenitis;
- kidney disease: chronic pyelonephritis, metabolic nephropathy;
- Diseases of the nervous system (including hereditary neurodegenerative diseases): migraine, autonomic nervous system disorders (NDC), mitochondrial encephalomyopathy (MELAS syndrome), Leig's syndrome, tuberous sclerosis, congenital myopathies, muscular dystrophies.
In the complex therapy of diseases associated with the violation of metabolic processes:
- asthenic syndrome;
- The recovery period after severe diseases and surgical interventions.
Adults and children over 1 year of age:
- for prophylaxis and replenishment of coenzyme deficiency Q 10 ;
- to improve the adaptation to increased physical exertion in athletes.
DOSING MODE
Couesan В® should be taken orally 1 time / day during meals in the morning, previously dissolved in a small amount of boiled water or other beverages at room temperature.
For the prevention of taking all the stated indications depending on the age in accordance with the data of Table 1.
Age Average dose Equivalent content of coenzyme Q 10
1-3 years 2-4 drops 3-6 mg
3-7 years 4-8 drops 6-12 mg
7-12 years 8-12 drops 12-18 mg
Children over 12 years and adults 12-24 drops 18-30 mg
In the complex treatment of various diseases, Couesan В® is administered depending on the age for all reported indications in accordance with the data in Table 2.
Age Average dose Equivalent content of coenzyme Q 10
1-3 years 4-10 drops 6-15 mg
3-7 years 10-16 drops 15-24 mg
7-12 years 16-20 drops 24-30 mg
Children over 12 years and adults 20-60 drops 30-90 mg
The duration of the course of the drug Kudesan В® is 2-3 months. It is possible to conduct repeated courses on the recommendation of a doctor.
SIDE EFFECT
From the side of the digestive system: very rarely - nausea, diarrhea.
Other : possibly allergic reactions.
CONTRAINDICATIONS
- Children's age up to 1 year;
- Hypersensitivity to the components of the drug.
Use with caution in arterial hypotension.
PREGNANCY AND LACTATION
The drug is not recommended for prescribing during pregnancy and during breastfeeding due to the lack of sufficient clinical experience.
APPLICATION FOR CHILDREN
Contraindication: children under 1 year.
OVERDOSE
No cases of drug overdose of Couesan В® were observed.
DRUG INTERACTION
The simultaneous use of lipid-lowering drugs (statins, fibrates), beta-blockers (atenolol, metoprolol, propranolol), tricyclic antidepressants can lead to a decrease in the concentration of ubidecarenone in the blood plasma.
Ubidekarenone can potentiate the action of diltiazem, metoprolol, enalapril and nitrates, and also reduce the effect of warfarin.
TERMS OF RELEASE FROM PHARMACY
The drug is released by prescription.
TERMS AND CONDITIONS OF STORAGE
The drug should be stored in a dry, protected from light, out of reach of children at a temperature of 15 В° to 25 В° C. Shelf life - 2 years.
